Addex Therapeutics Ltd

What they do

Addex Therapeutics is a Swiss biopharmaceutical company focused on discovering and developing oral small-molecule allosteric modulators that target G-protein-coupled receptors (GPCRs). Its lead program, ADX71149 (GABAB positive allosteric modulator), is licensed to Janssen Pharmaceuticals and is in clinical development for epilepsy. The company also has preclinical programs and, in 2024, spun out certain assets into Neurosterix, a separate entity. Addex operates through subsidiaries in Switzerland and France and is listed on Nasdaq as ADRs.

Revenue drivers

• Licensing and collaboration revenue — Addex receives payments from partners such as Janssen Pharmaceuticals for development activities and Indivior for patent maintenance, though amounts are not disclosed in the provided excerpts.
• Grant income — The company has historically received grants from Eurostars and Innosuisse for its mGlu2 NAM program, but these were discontinued as of April 2024.
• Neurosterix equity stake — Addex holds an equity interest in Neurosterix US Holdings LLC, which may provide future value but is not a direct revenue source.

Recent performance

The provided filing excerpts do not include specific revenue, net income, or cash figures for fiscal years 2023, 2024, or 2025. The only concrete financial data visible in the XBRL tags are share option exercise prices ranging from CHF 0.043 to CHF 3.00 and share capital amounts of 0.0025 and 0.10 per share, which do not constitute performance results. Operational updates include the discontinuation of the mGlu2 NAM program grant in April 2024 and the creation of Neurosterix. Without income statement or balance sheet data, recent financial performance cannot be summarized from this material.

Strategy

Addex is prioritizing the clinical advancement of its lead asset ADX71149 through its partnership with Janssen, while preserving capital by discontinuing non-core grant-funded programs such as mGlu2 NAM. The 2024 spin-out of Neurosterix allows the company to separate certain assets and potentially attract dedicated financing. Management appears focused on licensing and collaboration revenue to fund operations, as indicated by ongoing patent maintenance arrangements with Indivior. The company maintains a broad patent estate and continues to hold equity in Neurosterix. No new strategic initiatives beyond these are disclosed in the excerpts.

Risks

• Dependence on Janssen partnership — Addex's lead program ADX71149 is licensed to Janssen, so future revenue and clinical progress depend on Janssen's decisions and funding.
• Clinical development uncertainty — As a clinical-stage company, Addex faces inherent risks that its drug candidates will fail in trials or not receive regulatory approval.
• Capital constraints — With discontinued grant programs and limited disclosed revenue, Addex may need additional financing to fund ongoing operations.
• Reliance on Neurosterix value — The company's equity stake in Neurosterix could be volatile or illiquid, and its value is not guaranteed.

Outlook

The excerpts do not contain management's forward-looking statements or guidance. Based on the strategic moves described, Addex is likely to continue supporting the Janssen-partnered ADX71149 program while seeking to realize value from its Neurosterix holdings. However, without MD&A commentary or financial projections, a specific outlook cannot be provided from this material.